Sheela Rao1, Francesco Sclafani1, Cathy Eng2, Richard A Adams3, Marianne G Guren4, David Sebag-Montefiore5, Al Benson6, Annette Bryant1, Clare Peckitt1, Eva Segelov7, Amitesh Roy8, Matt T Seymour5, Jack Welch9, Mark P Saunders10, Rebecca Muirhead11, Peter O'Dwyer12, John Bridgewater13, Shree Bhide14, Rob Glynne-Jones15, Dirk Arnold12, David Cunningham1. 1. Royal Marsden Hospital, London, United Kingdom. 2. MD Anderson Cancer Center, Houston, TX. 3. Velindre Cancer Centre, Cardiff, Wales. 4. Oslo University Hospital, Oslo, Norway. 5. Leeds Cancer Centre, Leeds, United Kingdom. 6. Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL. 7. Monash Health and Monash University, Melbourne, VIC, Australia. 8. Flinders University and Flinders Medical Centre, Adelaide, SA, Australia. 9. National Cancer Institute, Bethesda, MD. 10. Christie Cancer Centre, Manchester, United Kingdom. 11. University of Oxford, Oxford, United Kingdom. 12. Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA. 13. University College Hospital, London, United Kingdom. 14. Institute of Cancer Research, London, United Kingdom. 15. Hamburg University Medical Centre, Hamburg, Germany.
Abstract
PURPOSE: To compare cisplatin plus fluorouracil (FU) versus carboplatin plus paclitaxel in chemotherapy-naïve advanced anal cancer to establish the optimal regimen. PATIENTS AND METHODS: Patients who had not received systemic therapy for advanced anal cancer were randomly assigned 1:1 to intravenous cisplatin 60 mg/m2 (day 1) plus FU 1,000 mg/m2 (days 1-4) every 21 days or carboplatin (area under the curve, 5; day 1) plus paclitaxel 80 mg/m2 (days 1, 8, and 15) every 28 days for 24 weeks, until disease progression, intolerable toxicity, or withdrawal of consent. Primary end point was objective response rate (ORR). Primary and secondary end points were assessed in a hierarchic model to compare the regimens and pick the winner. RESULTS: We conducted an international multicenter randomized phase II study in 60 centers between December 2013 and November 2017. Median follow-up was 28.6 months. A total of 91 patients were randomly assigned: 46 to cisplatin plus FU and 45 to carboplatin plus paclitaxel. ORR was 57% (95% CI, 39.4% to 73.7%) for cisplatin plus FU versus 59% (95% CI, 42.1% to 74.4%) for carboplatin plus paclitaxel. More serious adverse events were noted in the cisplatin plus FU arm (62%) compared with the carboplatin plus paclitaxel arm (36%; P = .016). Median progression-free survival was 5.7 months (95% CI, 3.3 to 9.0 months) for cisplatin plus FU compared with 8.1 months (95% CI, 6.6 to 8.8 months) for carboplatin plus paclitaxel. Median overall survival was 12.3 months for cisplatin plus FU (95% CI, 9.2 to 17.7 months) compared with 20 months (95% CI, 12.7 months to not reached) for carboplatin plus paclitaxel (hazard ratio, 2.00; 95% CI, 1.15 to 3.47; P = .014). CONCLUSION: This is the first international randomized trial to our knowledge conducted in chemotherapy-naïve advanced anal cancer. Although there was no difference in ORR, the association with clinically relevant reduced toxicity and a trend toward longer survival suggest that carboplatin plus paclitaxel should be considered as a new standard of care.
PURPOSE: To compare cisplatin plus fluorouracil (FU) versus carboplatin plus paclitaxel in chemotherapy-naïve advanced anal cancer to establish the optimal regimen. PATIENTS AND METHODS: Patients who had not received systemic therapy for advanced anal cancer were randomly assigned 1:1 to intravenous cisplatin 60 mg/m2 (day 1) plus FU 1,000 mg/m2 (days 1-4) every 21 days or carboplatin (area under the curve, 5; day 1) plus paclitaxel 80 mg/m2 (days 1, 8, and 15) every 28 days for 24 weeks, until disease progression, intolerable toxicity, or withdrawal of consent. Primary end point was objective response rate (ORR). Primary and secondary end points were assessed in a hierarchic model to compare the regimens and pick the winner. RESULTS: We conducted an international multicenter randomized phase II study in 60 centers between December 2013 and November 2017. Median follow-up was 28.6 months. A total of 91 patients were randomly assigned: 46 to cisplatin plus FU and 45 to carboplatin plus paclitaxel. ORR was 57% (95% CI, 39.4% to 73.7%) for cisplatin plus FU versus 59% (95% CI, 42.1% to 74.4%) for carboplatin plus paclitaxel. More serious adverse events were noted in the cisplatin plus FU arm (62%) compared with the carboplatin plus paclitaxel arm (36%; P = .016). Median progression-free survival was 5.7 months (95% CI, 3.3 to 9.0 months) for cisplatin plus FU compared with 8.1 months (95% CI, 6.6 to 8.8 months) for carboplatin plus paclitaxel. Median overall survival was 12.3 months for cisplatin plus FU (95% CI, 9.2 to 17.7 months) compared with 20 months (95% CI, 12.7 months to not reached) for carboplatin plus paclitaxel (hazard ratio, 2.00; 95% CI, 1.15 to 3.47; P = .014). CONCLUSION: This is the first international randomized trial to our knowledge conducted in chemotherapy-naïve advanced anal cancer. Although there was no difference in ORR, the association with clinically relevant reduced toxicity and a trend toward longer survival suggest that carboplatin plus paclitaxel should be considered as a new standard of care.
Authors: Paul F Engstrom; Juan Pablo Arnoletti; Al B Benson; Jordan D Berlin; J Michael Berry; Yi-Jen Chen; Michael A Choti; Harry S Cooper; Raza A Dilawari; Dayna S Early; Peter C Enzinger; Marwan G Fakih; James Fleshman; Charles Fuchs; Jean L Grem; James A Knol; Lucille A Leong; Edward Lin; Mary F Mulcahy; Eric Rohren; David P Ryan; Leonard Saltz; David Shibata; John M Skibber; William Small; Constantinos Sofocleous; James Thomas; Alan P Venook; Christopher Willett Journal: J Natl Compr Canc Netw Date: 2010-01 Impact factor: 11.908
Authors: H Bartelink; F Roelofsen; F Eschwege; P Rougier; J F Bosset; D G Gonzalez; D Peiffert; M van Glabbeke; M Pierart Journal: J Clin Oncol Date: 1997-05 Impact factor: 44.544
Authors: M Flam; M John; T F Pajak; N Petrelli; R Myerson; S Doggett; J Quivey; M Rotman; H Kerman; L Coia; K Murray Journal: J Clin Oncol Date: 1996-09 Impact factor: 44.544
Authors: Mohamed E Salem; Benjamin A Weinberg; Samantha A Armstrong; Rita Malley; Hongkun Wang; Heinz-Josef Lenz; David Arguello; Wafik S El-Deiry; Joanne Xiu; Zoran Gatalica; Jimmy J Hwang; Philip A Philip; Anthony F Shields; John L Marshall Journal: J Gastrointest Oncol Date: 2021-10
Authors: Robert Hester; Shailesh Advani; Asif Rashid; Emma Holliday; Craig Messick; Prajnan Das; Yi-Qian N You; Cullen Taniguchi; Eugene J Koay; Brian Bednarski; Miguel Rodriguez-Bigas; John Skibber; Robert Wolff; George J Chang; Bruce D Minsky; Wai Chin Foo; Nicole Rothschild; Van K Morris; Cathy Eng Journal: Oncotarget Date: 2021-05-25
Authors: Wojciech Snoch; Dawid Wnuk; Tomasz Witko; Jakub Staroń; Andrzej J Bojarski; Ewelina Jarek; Francisco J Plou; Maciej Guzik Journal: Int J Mol Sci Date: 2021-07-05 Impact factor: 5.923
Authors: Robert Siegel; Ricardo Niklas Werner; Stephan Koswig; Matthew Gaskins; Claus Rödel; Felix Aigner Journal: Dtsch Arztebl Int Date: 2021-04-02 Impact factor: 8.251
Authors: Joanna Gotfrit; Rachel Goodwin; Timothy Asmis; Angela J Hyde; Thierry Alcindor; Francine Aubin; Scott Berry; Dominick Bossé; Colin Brown; Ronald Burkes; Margot Burnell; Bruce Colwell; Jessica Corbett; Jeff Craswell; Nathalie Daaboul; Mark Doherty; D A Barry Fleming; Luisa Galvis; Rakesh Goel; Mohammed Harb; Alwin Jeyakumar; Derek Jonker; Erin Kennedy; Michael Lock; Aamer Mahmud; Patrick H McCrea; Vimoj Nair; Rami Nassabein; Carolyn Nessim; Ravi Ramjeesingh; Muhammad Raza; Wissam Saliba; Satareh Samimi; Simron Singh; Stephanie Snow; Mustapha Tehfé; Michael Thirlwell; Mario Valdes; Stephen Welch; Michael Vickers Journal: Curr Oncol Date: 2021-05-26 Impact factor: 3.677